43
Participants
Start Date
January 31, 2007
Primary Completion Date
September 30, 2011
Study Completion Date
September 30, 2011
filgrastim
Supportive therapy: GF therapy with G-CSF, GM-CSF, or pegfilgrastim will be used in all patients, beginning on Day 3 of each cycle, until post nadir of blood counts from each chemotherapy cycle.
pegfilgrastim
GF therapy with G-CSF, GM-CSF, or pegfilgrastim will be used in all patients, beginning on Day 3 of each cycle, until post nadir of blood counts from each chemotherapy cycle.
rituximab
375 mg/m2 IV Day 1 of each cycle
sargramostim
GF therapy with G-CSF, GM-CSF, or pegfilgrastim will be used in all patients, beginning on Day 3 of each cycle, until post nadir of blood counts from each chemotherapy cycle.
cyclophosphamide
750 mg/m2 IV Day 1 of each cycle
pegylated liposomal doxorubicin hydrochloride
40 mg/m2 IV Day 1 of each cycle
prednisone
100 mg PO Days 1-5 of each cycle
vincristine sulfate
1.4 mg/m2 IV Day 1 (2.0 mg maximum) of each cycle
immunohistochemistry staining method
tissue specimen collected at baseline
laboratory biomarker analysis
tissue specimen collected at baseline
Memorial Sloan-Kettering Cancer Center, New York
Albert Einstein Cancer Center at Albert Einstein College of Medicine, The Bronx
Joan Karnell Cancer Center at Pennsylvania Hospital, Philadelphia
University of Miami Sylvester Comprehensive Cancer Center - Miami, Miami
Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis, St Louis
Ochsner Cancer Institute at Ochsner Clinic Foundation, New Orleans
Virginia Mason Medical Center, Seattle
Rebecca and John Moores UCSD Cancer Center, La Jolla
USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles
UCLA Clinical AIDS Research and Education (CARE) Center, Los Angeles
Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago
Boston University Cancer Research Center, Boston
Beth Israel Deaconess Medical Center, Boston
Case Comprehensive Cancer Center, Cleveland
National Cancer Institute (NCI)
NIH
The Emmes Company, LLC
INDUSTRY
AIDS Malignancy Consortium
NETWORK